Visikol Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $7.5M

Visikol General Information

Description

Developer of tissue clearing and 3D imaging technology catering to researchers, developers and pathologists in the drug discovery sector. The company offers technology based on vitro cell culture that leverages the company technology combined with confocal imaging and quantitative histology to provide 3D in vitro assays that extract all the data from advanced models, thereby enabling clients to capture high-resolution images in 3D from biological tissues.

Contact Information

Website
www.visikol.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Corporate Office
  • 53 Frontage Road
  • Suite 120, Shelbourne Building
  • Hampton, NJ 08827
  • United States
+1 (800) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Visikol Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 20-May-2021 $7.5M 00000 00.00 Completed Generating Revenue
6. Grant 01-May-2021 00000 00000 Completed Generating Revenue
5. Grant 17-Apr-2019 00000 00000 Completed Generating Revenue
4. Early Stage VC 30-Dec-2017 00000 Completed Generating Revenue
3. Grant 31-Dec-2016 0000 00000 Completed Generating Revenue
2. Grant 20-Jun-2016 $225K $500K Completed Generating Revenue
1. Seed Round 23-Feb-2016 $500K $500K 000 Completed Generating Revenue
To view Visikol’s complete valuation and funding history, request access »

Visikol Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of tissue clearing and 3D imaging technology catering to researchers, developers and pathologists in the drug
Drug Discovery
Hampton, NJ
12 As of 2021
00000
00.00 0000-00-00
000000&0 00000

000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000 000000000
Kulmbach, Germany
00 As of 0000
000000000000

00000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. D
0000000000000
San Diego, CA
00 As of 0000
00000
00.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Visikol Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axolabs Private Equity-Backed Kulmbach, Germany 00 000000000000
Ambrx Formerly PE-Backed San Diego, CA 00 00000 000000&0 00000
Aspect Biosystems Venture Capital-Backed Vancouver, Canada 000 000.00 0000000000 0 000.00
Hesperos Venture Capital-Backed Orlando, FL 00 00000000
Organovo Formerly VC-backed San Diego, CA 00 0000 00000000 0000
You’re viewing 5 of 12 competitors. Get the full list »

Visikol Patents

Visikol Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210382040-A1 Detection of biologicals penetration into tissue surrogates Pending 26-Sep-2018 0000000000
EP-3857200-A1 Detection of biologicals penetration into tissue surrogates Inactive 26-Sep-2018 0000000000
EP-3857200-A4 Detection of biologicals penetration into tissue surrogates Inactive 26-Sep-2018 00000000 0
US-20180021285-A1 Method for visualization of calcium containing components in biological systems Inactive 25-Jul-2016 C09B1/02

Visikol Executive Team (4)

Name Title Board Seat Contact Info
Thomas Villani Ph.D Chief Science Officer & Co-Founder
Brian Mulhall Director of Operations
You’re viewing 2 of 4 executive team members. Get the full list »

Visikol Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Visikol Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alan Weiss Angel (individual) Minority 000 0000 000000 0
Brian Mulhall Angel (individual) Minority 000 0000 000000 0
Foundation Venture Capital Group Venture Capital Minority 000 0000 000000 0
National Science Foundation Government Minority 000 0000 000000 0
To view Visikol’s complete investors history, request access »

Visikol FAQs

  • When was Visikol founded?

    Visikol was founded in 2012.

  • Who is the founder of Visikol?

    Nick Crider, Thomas Villani Ph.D, and Michael Johnson Ph.D are the founders of Visikol.

  • Where is Visikol headquartered?

    Visikol is headquartered in Hampton, NJ.

  • What is the size of Visikol?

    Visikol has 12 total employees.

  • What industry is Visikol in?

    Visikol’s primary industry is Drug Discovery.

  • Is Visikol a private or public company?

    Visikol is a Private company.

  • What is the current valuation of Visikol?

    The current valuation of Visikol is 00.00.

  • What is Visikol’s current revenue?

    The current revenue for Visikol is 00000.

  • How much funding has Visikol raised over time?

    Visikol has raised $500K.

  • Who are Visikol’s investors?

    Alan Weiss, Brian Mulhall, Foundation Venture Capital Group, and National Science Foundation have invested in Visikol.

  • Who are Visikol’s competitors?

    Axolabs, Ambrx, Aspect Biosystems, Hesperos, and Organovo are some of the 12 competitors of Visikol.

  • When was Visikol acquired?

    Visikol was acquired on 20-May-2021.

  • Who acquired Visikol?

    Visikol was acquired by BICO Group.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »